United States Patent 11,911,388: Linagliptin Patent Scope, Claims, Exclusivity, and Patent Landscape
US Patent No. 11,911,388 covers a narrow method of using linagliptin, the active ingredient in Tradjenta, for type 2 diabetes patients with renal impairment who remain inadequately controlled on metformin alone or metformin combined with insulin or an insulin analogue. The central limitation is oral linagliptin at 5 mg once daily in combination with metformin, with certain claims extending to basal insulin combinations and specified glycemic outcomes.
The patent does not claim linagliptin as a chemical compound, linagliptin generally, or every use of linagliptin in renal impairment. Its enforceable scope depends on proving the patient population, prior treatment failure, renal impairment, combination therapy, dose, and, for some claims, the specified clinical outcome.
What drug does US Patent 11,911,388 protect?
The claimed active ingredient is linagliptin, chemically identified in the claims as:
1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine.
Linagliptin is an orally administered, once-daily dipeptidyl peptidase-4, or DPP-4, inhibitor. It is marketed in the United States as Tradjenta by Boehringer Ingelheim Pharmaceuticals and Eli Lilly.
The claims cover linagliptin in free-base form or as a pharmaceutically acceptable salt. Claim 5 narrows the subject matter to the free base. The claimed dose is 5 mg per day, matching the standard approved Tradjenta dose.
What therapeutic setting is covered?
The patent targets patients with:
- Type 2 diabetes;
- Renal impairment;
- Insufficient glycemic control;
- Prior treatment with metformin monotherapy, or metformin combined with insulin or an insulin analogue.
The claims also identify elderly patients and patients receiving basal insulin. The patent therefore focuses on treatment sequencing and patient selection rather than on a new molecule or a new formulation.
How do the claims of US 11,911,388 work?
Claim-by-claim scope
| Claim |
Principal limitation |
Scope |
| 1 |
Linagliptin 5 mg orally daily for inadequately controlled type 2 diabetes patients with renal impairment after metformin or metformin plus insulin |
Independent method claim |
| 2 |
Inadequate control specifically after metformin monotherapy |
Narrows claim 1 |
| 3 |
Improvement in HbA1c, fasting plasma glucose, postprandial glucose, glucose excursion, or insulin secretion |
Outcome limitation |
| 4 |
Elderly patients |
Patient subgroup |
| 5 |
Linagliptin in free-base form |
Chemical-form limitation |
| 6 |
Metformin alone or metformin plus basal insulin |
Treatment-history limitation |
| 7 |
5 mg linagliptin plus metformin in inadequately controlled type 2 diabetes |
Specific combination regimen |
| 8 |
5 mg linagliptin plus metformin and insulin or an insulin analogue |
Triple-therapy regimen |
| 9 |
Reduction in the required dose of metformin, insulin, or insulin analogue |
Dose-sparing outcome |
| 10 |
5 mg once daily, with or without food |
Administration schedule |
| 11 |
Steady-state plasma levels reached between days two and five |
Pharmacokinetic limitation |
Claim 1 is the commercial center of gravity. Claims 7 and 8 are more specific and may be important against products or promotional materials that expressly recommend linagliptin in combination with metformin, with or without insulin.
What must be proven for infringement?
A branded or generic product would not infringe merely because it contains linagliptin or is prescribed to a patient with kidney disease. A method claim requires proof that the claimed treatment method was practiced or induced.
The relevant facts include:
- The patient has type 2 diabetes.
- The patient has renal impairment.
- Glycemic control is inadequate.
- The patient previously received metformin monotherapy or metformin plus insulin or an insulin analogue.
- The product contains linagliptin.
- The administered dose is 5 mg orally per day.
- For narrower claims, the treatment involves the claimed combination, patient subgroup, or clinical result.
The claim language does not expressly define a creatinine-clearance threshold or specific chronic kidney disease stage. That omission broadens the potential patient population but creates claim-construction issues. The renal-impairment limitation must be interpreted against the specification, prosecution history, and ordinary clinical meaning.
What is the strongest claim in US Patent 11,911,388?
Claim 1 is the broadest claim, but claim 7 may be the most commercially significant.
Claim 1 covers:
- Renally impaired type 2 diabetes patients;
- Prior metformin treatment, either alone or with insulin;
- 5 mg oral linagliptin;
- Combination use with metformin or metformin-plus-insulin therapy.
Claim 7 is narrower because it requires metformin combination therapy without the insulin component. It may be easier to prove when the prescribing information or product labeling expressly identifies linagliptin as an add-on to metformin.
Claim 8 is narrower still and applies to triple therapy with metformin and insulin or an insulin analogue. Its practical value depends on whether a generic label includes that indication and whether the manufacturer’s marketing materials encourage the combination.
Claim 11 is technically narrow. It requires steady-state plasma levels to be reached between the second and fifth day. Such a limitation may create proof problems because ordinary prescribing information may not state or promote the claimed pharmacokinetic timing.
What does the patent exclude?
The claims do not expressly cover:
- Linagliptin for type 1 diabetes;
- Linagliptin monotherapy;
- Linagliptin combined only with a sulfonylurea, SGLT2 inhibitor, or GLP-1 receptor agonist;
- Doses other than 5 mg per day;
- Non-oral administration;
- Linagliptin products lacking a method-of-use connection to the claimed patient population;
- A new linagliptin formulation;
- The chemical composition of linagliptin itself;
- Manufacturing processes for linagliptin.
A product label that omits the patented renal-impairment and combination-use language may reduce inducement exposure, although actual promotional conduct, physician knowledge, clinical practice, and the complete label remain relevant.
When does US Patent 11,911,388 lose exclusivity?
The patent’s expiration date must be determined from its priority chain, patent-term adjustment, terminal disclaimers, and any applicable patent-term extension. The claims supplied do not establish those dates.
The patent is a later-issued method-of-use patent associated with the linagliptin franchise. Its remaining term is distinct from the basic linagliptin compound patent and from other formulation or therapeutic-use patents. A generic applicant must evaluate each enforceable patent independently.
Patent-term factors
| Factor |
Relevance |
| Earliest effective nonprovisional priority date |
Establishes the basic 20-year term |
| Continuation or divisional status |
May preserve the original family term |
| Patent-term adjustment |
Can extend the nominal expiration date |
| Terminal disclaimer |
Can tie expiration to an earlier patent |
| Patent-term extension |
May apply only to qualifying regulatory delay |
| Orange Book listing date |
Affects notice and litigation timing, not the basic patent term |
US Patent 11,911,388 was issued on March 5, 2024. Its issue date does not determine expiration. A reliable freedom-to-operate conclusion requires the complete continuity statement and USPTO term data rather than the claims alone. [1]
Is US Patent 11,911,388 listed in the Orange Book?
Orange Book status must be checked against the current FDA Approved Drug Products with Therapeutic Equivalence Evaluations database and the patent information submitted for the Tradjenta NDA.
The patent concerns an approved method of using linagliptin and therefore is the type of patent that may be submitted for Orange Book listing under FDA regulations. Listing depends on the NDA holder’s certification and FDA acceptance of the patent information. A patent number appearing in a patent database does not by itself establish Orange Book listing.
For a listed method-of-use patent, an abbreviated new drug application applicant may be required to submit:
- A Paragraph III certification stating that the patent will not expire before approval;
- A Paragraph IV certification alleging that the patent is invalid, unenforceable, or not infringed;
- A section viii statement carving out the patented method, if the remaining unpatented uses support approval.
The strategic importance of US 11,911,388 therefore depends on the exact Orange Book use code. A narrow use code may permit a label carve-out. A broad use code covering the principal approved renal-impairment or combination indication may create greater launch risk.
What Paragraph IV challenges could affect linagliptin?
A Paragraph IV challenge to US 11,911,388 would likely focus on claim construction, written description, enablement, obviousness, anticipation, and inducement.
Likely invalidity theories
Obviousness
The principal vulnerability is obviousness over:
- Earlier linagliptin compound patents;
- DPP-4 inhibitor treatment guidelines;
- Metformin add-on studies;
- Renal-impairment pharmacokinetic studies;
- Clinical literature concerning linagliptin dosing in chronic kidney disease;
- Prior art involving insulin combination therapy.
The patentee would likely argue that the claimed combination of patient selection, dose, and treatment history produced clinically useful results without requiring renal dose adjustment. A court would assess whether the complete combination was suggested by the prior art and whether the claimed population was reasonably predictable.
Anticipation
Anticipation would require a single prior-art reference to disclose all material limitations, including:
- Renal impairment;
- Inadequate control after metformin;
- 5 mg daily linagliptin;
- The claimed combination;
- The relevant patient subgroup or outcome where applicable.
General disclosures of linagliptin for diabetes would not necessarily anticipate the claims.
Written description and enablement
The claims cover a broad renal-impairment population without a numerical kidney-function threshold. A challenger could argue that the specification does not adequately support every degree of renal impairment or every combination with insulin analogues. The patentee would rely on clinical data, pharmacokinetic data, and the established pharmacology of linagliptin.
Indefiniteness
Terms such as “renal impairment,” “insufficient glycemic control,” “elderly,” and “improving insulin secretion” may generate claim-construction disputes. The risks are greater for claim 3, claim 4, and claim 11 than for the core 5 mg combination claims.
How does the patent compare with the broader linagliptin estate?
The linagliptin estate has several distinct layers.
| Estate layer |
Typical subject matter |
Relevance to US 11,911,388 |
| Compound patents |
Linagliptin and related xanthine derivatives |
Protect the molecule itself |
| Salt and crystal patents |
Pharmaceutical salts, polymorphs, solid forms |
May affect API and product manufacture |
| Formulation patents |
Tablets, excipients, release characteristics |
May affect product composition |
| Method-of-use patents |
Diabetes, renal impairment, combination therapy |
Directly relevant |
| Combination patents |
Linagliptin with metformin or insulin |
Overlap risk with claims 7 and 8 |
| Manufacturing patents |
Intermediate compounds and synthesis steps |
API sourcing risk |
| Regulatory exclusivity |
FDA drug exclusivity periods |
Separate from patent rights |
The foundational linagliptin compound patent is US 7,407,955, assigned to Boehringer Ingelheim and directed to xanthine derivatives including linagliptin. Its term is materially different from the later method patent. [2]
Later patents in the family and related families may cover dosage regimens, diabetic nephropathy, combination treatment, and pharmaceutical compositions. Patent-family analysis is essential because a generic launch may clear US 11,911,388 yet remain blocked by an earlier compound, formulation, or separate use patent.
What formulation patents protect Tradjenta?
US 11,911,388 is not a formulation patent. It does not claim tablet excipients, coating, dissolution performance, particle size, or a particular manufacturing process.
Formulation risk must be assessed separately through:
- Orange Book-listed patents for the Tradjenta NDA;
- Patent-family records assigned to Boehringer Ingelheim or related entities;
- FDA product-label and dosage-form information;
- API and solid-form patents;
- Any patents covering fixed-dose combinations such as linagliptin-metformin products.
A manufacturer can avoid infringement of a formulation claim by using a noninfringing formulation while still infringing a method claim through labeling or induced use.
What manufacturing and API risks exist?
Linagliptin API supply can remain constrained after the compound patent expires because process, intermediate, salt, polymorph, and regulatory-approval issues may persist.
The key manufacturing questions are:
- Whether the supplier uses a patented synthetic route;
- Whether the API is the claimed free base or a protected salt or solid form;
- Whether the finished tablet uses a protected formulation;
- Whether process patents have enforceable US claims;
- Whether the supplier has completed FDA DMF and inspection requirements.
Claim 5 of US 11,911,388 does not create a manufacturing monopoly over the free base. It covers use of the free base in the claimed clinical method. A process manufacturer therefore faces separate analysis under process and composition patents.
What litigation and settlement risks affect generic launch?
A Paragraph IV notice involving a listed patent can trigger a Hatch-Waxman action within 45 days and a 30-month stay of FDA approval, subject to statutory exceptions. [3]
For US 11,911,388, litigation risk would depend on:
- Whether the patent is listed for the relevant Tradjenta NDA;
- Whether an ANDA applicant certifies Paragraph IV;
- Whether the applicant uses a section viii carve-out;
- Whether the patent owner sues within the statutory period;
- Whether earlier linagliptin patents are also asserted;
- Whether a settlement permits a date-certain launch.
Settlement agreements should be reviewed for:
- Authorized-generic rights;
- Launch dates;
- Patent challenges and no-challenge provisions;
- Product supply obligations;
- Acceleration clauses;
- Restrictions on renal-impairment or combination labeling.
No settlement should be inferred from the existence of the patent alone. The operative documents and FTC filings control.
How strong is the patent estate?
US 11,911,388 has moderate claim breadth and potentially meaningful commercial leverage.
Strengths
- It targets a common clinical population.
- The 5 mg dose matches the marketed product.
- Metformin combination therapy is commercially routine.
- The claims cover renal impairment, where linagliptin has a differentiated dosing profile.
- Claims 7 and 8 map onto recognizable treatment pathways.
Weaknesses
- The claims are method claims, not composition claims.
- Several limitations depend on clinical history and physician conduct.
- The renal-impairment boundary is not numerically specified.
- Prior art on DPP-4 inhibitors, metformin, insulin, and renal dosing may support obviousness arguments.
- A generic applicant may attempt a label carve-out.
- Claims 3, 9, and 11 contain outcome or pharmacokinetic limitations that may be difficult to prove.
The patent is strongest where a label expressly instructs physicians to use 5 mg linagliptin with metformin in renally impaired patients whose prior metformin therapy was inadequate. It is weaker where the alleged use depends on off-label physician behavior or an unadvertised clinical outcome.
What generic launch scenarios exist?
| Scenario |
Commercial effect |
| Paragraph III certification |
Launch waits until patent expiration |
| Paragraph IV challenge with litigation |
Approval may be delayed by litigation and statutory stay |
| Section viii carve-out |
Generic may launch for unpatented uses if the label is adequate |
| Successful invalidity or noninfringement case |
Launch may proceed before expiry |
| Settlement with agreed launch date |
Launch follows contractual terms |
| Authorized generic launch |
Price erosion may begin before independent generic entry |
| Noninfringing label and promotion |
Reduces inducement exposure but does not eliminate all risk |
The highest-risk launch is a full-label generic that expressly retains renal-impairment and metformin add-on instructions. The lower-risk route is a properly supported skinny label excluding the patented use, subject to FDA approval and actual commercial conduct.
What is the revenue exposure?
The patent’s revenue exposure is linked to the renal-impaired, metformin-treated segment rather than to all Tradjenta prescriptions. A realistic exposure analysis should segment:
- Monotherapy use;
- Metformin add-on use;
- Metformin-plus-insulin use;
- Renally impaired patients;
- Elderly patients;
- Products sold as Tradjenta;
- Fixed-dose linagliptin-metformin products;
- Hospital and outpatient prescribing.
A patent covering only a subset of prescriptions may still delay generic entry if FDA approval depends on a label that includes the patented indication. Conversely, a successful section viii carve-out can preserve generic entry while leaving the patented patient segment protected.
Key Takeaways
- US Patent 11,911,388 is a narrow method-of-use patent for 5 mg oral linagliptin in renally impaired type 2 diabetes patients inadequately controlled on metformin-based therapy.
- The key commercial claims are claims 1, 7, and 8.
- The patent does not claim linagliptin as a molecule, a formulation, or a manufacturing process.
- Infringement depends on patient characteristics, prior treatment, dose, combination therapy, and physician or label conduct.
- A Paragraph IV challenge would likely focus on obviousness, claim construction, written description, enablement, and inducement.
- A section viii carve-out may be available if the FDA-approved label can omit the patented renal-impairment combination use.
- The patent must be analyzed with the broader linagliptin compound, formulation, salt, solid-form, manufacturing, and method-of-use portfolio.
- Patent expiration, Orange Book listing, and settlement status require review of the current USPTO and FDA records, not the claim text alone.
FAQs
Does US Patent 11,911,388 cover all renal-impaired patients taking linagliptin?
No. The claims require type 2 diabetes, inadequate glycemic control, the specified metformin-based treatment history, and 5 mg oral linagliptin. Some claims add insulin, basal insulin, elderly status, or specified outcomes.
Can a generic linagliptin company avoid this patent by using a dose other than 5 mg?
A different dose would not satisfy the express 5 mg limitation, but it may implicate other patents, regulatory requirements, or clinical-use claims. Dose substitution also may not be commercially viable because 5 mg is the approved standard dose.
Is linagliptin safe to use in patients with renal impairment without dose adjustment?
The FDA label identifies 5 mg once daily as the recommended Tradjenta dose and does not require renal dose adjustment. The label, not the patent, governs approved prescribing. [4]
Does a patent on the method block approval of a generic linagliptin product?
Not necessarily. An ANDA applicant may use a Paragraph III certification, Paragraph IV certification, or section viii statement depending on the patent listing and the proposed label.
Does US Patent 11,911,388 protect linagliptin-metformin fixed-dose tablets?
Not directly. The claims recite administration of linagliptin in combination with metformin, but they do not claim a particular fixed-dose tablet formulation. Separate formulation and combination-product patents may apply.
References
- United States Patent and Trademark Office. (2024). U.S. Patent No. 11,911,388.
- United States Patent and Trademark Office. (2008). U.S. Patent No. 7,407,955.
- Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 355(j).
- U.S. Food and Drug Administration. (2023). Tradjenta (linagliptin) prescribing information. Boehringer Ingelheim Pharmaceuticals, Inc.
